ReviewMolecular cancer2026
Ferroptosis in cancer toward molecular insights and clinical translation in pancreatic cancer.
Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Selenium-Thioredoxin Axis Contributes to Ferroptosis Resistance in Pancreatic Cancer Cells.International journal of molecular sciences · 2026Article
- Ferroptosis, pyroptosis, and necroptosis in melanoma: regulatory cell death pathways and their implications for immunotherapy.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Ferroptosis is a regulated form of cell death driven by iron accumulation and lipid peroxidation. Since its recognition as a modality of regulated cell death, ferroptosis has attracted increasing attention in cancer research for its distinct metabolic and redox dependencies. Recent evidence suggests that ferroptosis arises from systems-level regulation integrating metabolic reprogramming, gene and RNA control, and inter-organelle communication, while simultaneously influencing immune remodeling and the tumor microenvironment. These processes collectively determine ferroptosis susceptibility and therapeutic response. Ferroptosis-related genes and pathways have also emerged as potential biomarkers for risk stratification, treatment prediction, and imaging-based assessment. Moreover, small-molecule inducers, targeted inhibitors, and delivery systems capable of modulating ferroptosis demonstrate translational potential to overcome therapeutic resistance across multiple malignancies, including pancreatic cancer. This review synthesizes recent mechanistic and translational advances, highlighting ferroptosis as a conceptual bridge between cellular metabolism and tumor therapy, and outlining perspectives for precision diagnostics and personalized interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.